{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:09Z","timestamp":1789604109674,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006751","name":"U.S. Army","doi-asserted-by":"publisher","award":["IMG0402501"],"award-info":[{"award-number":["IMG0402501"]}],"id":[{"id":"10.13039\/100006751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["032047"],"award-info":[{"award-number":["032047"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["BC024118"],"award-info":[{"award-number":["BC024118"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005640","name":"Flight Attendant Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.surg.2014.03.031","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T23:00:25Z","timestamp":1403305225000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently"],"prefix":"10.1016","volume":"156","author":[{"given":"Justin W.","family":"Ady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J.","family":"Belin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Tung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amudhan","family":"Pugalenthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanhai G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladar A.","family":"Szalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2014.03.031_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2014.03.031_bib2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2014.03.031_bib3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.surg.2014.03.031_bib4","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2014.03.031_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2014.03.031_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.surg.2014.03.031_bib7","doi-asserted-by":"crossref","first-page":"e22069","DOI":"10.1371\/journal.pone.0022069","article-title":"Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68","volume":"6","author":"Gentschev","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.surg.2014.03.031_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5694\/j.1326-5377.1999.tb123833.x","article-title":"Nature, nurture and my experience with smallpox eradication","volume":"171","author":"Fenner","year":"1999","journal-title":"Med Jof Australia"},{"key":"10.1016\/j.surg.2014.03.031_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1462-5822.2009.01327.x","article-title":"Vaccinia-induced epidermal growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to suppress cell death during infection","volume":"11","author":"Postigo","year":"2009","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.surg.2014.03.031_bib10","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2014.03.031_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Blivet-Van Eggelpoel","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.surg.2014.03.031_bib12","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2014.03.031_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","article-title":"Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth","volume":"329","author":"van Malenstein","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.surg.2014.03.031_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1535-7163.MCT-11-0412","article-title":"Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3","volume":"11","author":"Tai","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.surg.2014.03.031_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.110.175786","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"337","author":"Chen","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.surg.2014.03.031_bib16","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.27604","article-title":"EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib","volume":"131","author":"Ezzoukhry","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.surg.2014.03.031_bib17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1440-1746.2012.07060.x","article-title":"Epithelial-mesenchymal transition and the liver: role in hepatocellular carcinoma and liver fibrosis","volume":"27","author":"Maheswaran","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.surg.2014.03.031_bib18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.surg.2014.03.031_bib19","first-page":"S11","article-title":"Emerging targeted strategies in advanced hepatocellular carcinoma","volume":"33","author":"Finn","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.surg.2014.03.031_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","article-title":"Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma","volume":"69","author":"Petrini","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.surg.2014.03.031_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000320363","article-title":"Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment","volume":"79","author":"Worns","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.surg.2014.03.031_bib22","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","article-title":"Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma","volume":"18","author":"Finn","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2014.03.031_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2014.03.031_bib24","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s12032-012-0208-x","article-title":"Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib","volume":"29","author":"Mir","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.surg.2014.03.031_bib25","first-page":"1170","article-title":"Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy","volume":"19","author":"Heo","year":"2011","journal-title":"Mol The"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606014001251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606014001251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:51:01Z","timestamp":1758538261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606014001251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0039606014001251"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2014.03.031","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2014.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}